EU-Ocrevus

BIOLOGICAL2 trials

Sponsors

Celltrion, Polpharma Biologics International AG

Conditions

Multiple SclerosisRelapsing-remitting Multiple Sclerosis

Phase 1

A Biosimilar Trial to Investigate PK, PD, Safety With PB018 Versus US-licensed Ocrevus and EU-approved Ocrevus

Not yet recruitingNCT07606521

Polpharma Biologics International AGMultiple Sclerosis

Start: 2026-10-01End: 2028-04-01Target: 222Updated: 2026-05-28

Phase 3

A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis

RecruitingNCT05906992

CelltrionRelapsing-remitting Multiple Sclerosis

Start: 2024-01-11End: 2029-01-31Target: 512Updated: 2024-05-22